Part 4 of 5 in our series: What Makes a Modern CRO?
Inside HiRO’s Global Growth Story
The New Operational Reality of Global Clinical Trials
Running a trial across borders used to mean managing time zones, languages, and site logistics. Increasingly, it also means managing where patient data physically lives, who can access it, and under what legal framework it can cross a border at all.
HiRO Founder & CEO, Karen Chu argues this shouldn’t be treated as an obstacle to global development, it’s simply the new operating environment. Sponsors who plan for it early come out ahead.
Two Countries, Two Data Environments
HiRO’s own infrastructure reflects this reality directly: the company operates separate data environments in China and the United States, with dedicated safeguards between them that reflect the different regulatory requirements each market imposes. This isn’t a workaround. It’s a structural response to genuinely different legal regimes. China has introduced stringent data privacy and cybersecurity requirements that add real steps for any company handling health data or transferring it internationally, and similar dynamics are emerging in other jurisdictions as data governance rules continue to tighten globally.
More Procedure, Not Less Opportunity
For sponsors, the practical effect is more procedural overhead: additional compliance steps, more careful data infrastructure planning, and more upfront work to ensure a multi-country trial design actually holds up legally in every jurisdiction it touches. That’s a real cost. But it’s worth reframing what that cost buys.
Operating across multiple regulatory regimes also functions as a form of risk management. A development program that depends entirely on one jurisdiction is exposed to that jurisdiction’s policy shifts, enforcement priorities, and political dynamics. A program structured across several regions, with the right data safeguards built in from the start, gives sponsors more room to balance opportunities against constraint, rather than betting the whole program on a single regulatory environment staying stable.
What This Means for How Sponsors Should Plan
The organizations navigating this well tend to share one habit: they treat data governance as a design question at the start of a trial, not a compliance question to solve after the protocol is locked. That means:
- Mapping which jurisdictions the trial will touch, including where data is stored, not just where sites are located, before finalizing the design.
- Building data environments and transfer safeguards into the trial infrastructure from day one, rather than retrofitting them.
- Treating multi-jurisdiction complexity as a structural hedge, not just a cost center, when deciding where to run a program.
Geopolitical and regulatory conditions will keep shifting; that’s not going away. But sponsors who build compliant, well-structured multi-region infrastructure from the outset are the ones positioned to keep moving quickly no matter which direction those conditions shift.
